


TB: When it is not your Average Case-Multidrug Resistant TB and Extensively Drug Resistant TB

**Satellite Conference and Live Webcast
Tuesday, December 4, 2018
9:00 – 10:30 a.m. Central Time**


Produced by the Alabama Department of Public Health
Video Communications and Distance Learning Division

Faculty

**Karen M. Landers, MD, FAAP
Medical Consultant TB Control
Alabama Department of Public Health**



Primary infection with cavitation



TB: Multidrug Resistant (MDR)

- Resistant to at least INH and Rifampin
- Requires additional considerations for treatment including second line drugs

Concerns about Multidrug Resistant Tuberculosis

- Previous therapy for TB, especially if recent, increases risk for MDR
- Foreign born persons from countries or ethnicities with increased MDR are at risk
- Persons with poor response to standard four drug therapy could be MDR

Concerns about Multidrug Resistant Tuberculosis

- Persons with known exposure to MDR patients are at risk for MDR
- Persons who are HIV positive can respond poorly to standard therapy and acquire MDR

– Francis J. Curry, MDR

Extensively Drug Resistant TB

- Multidrug Resistant tuberculosis plus
- Resistance to a fluoroquinolone AND
- At least one of three injectables
 - Amikacin
 - Kanamycin
 - Capreomycin
- Very challenging treatment regimen for extended length of time

Concerns about Extensively Drug Resistant Tuberculosis (XDR)

- Multiple factors increase the risk for XDR
 - Introduction of second line TB drugs into low and middle income countries
 - Suboptimal TB control practices
 - High HIV prevalence
 - High burden of tuberculosis

Francis J. Curry, MDR

Key Concerns for MDR and XDR for Tuberculosis Control

- Prevention of acquired resistance to standard regimens
- Prevention of transmission of MDR or XDR to contacts
- Prevention of progression to disease in those infected with MDR or XDR

Diagnosis of Multidrug Resistant or Extensively Drug Resistant TB

- NAAT (PCR)
- MDDR
- HAIN
- Culture still gold standard

Treatment of Multidrug Resistant / Extensively Drug Resistant TB

- Consultation with an expert (sometimes multiple experts)
- General principles of initial drug regimen
- Need for close ongoing monitoring
- Challenges of side effects/tolerance of drug regimens
- Length of regimens

Case Discussions

- **Case from Vietnam**
- **Case from Nigeria**
- **Case from China**

Tuberculosis Specific Websites

- **www.cdc.gov/tb**
- **<http://sntc.medicine.ufl.edu>**
- **www.currytbcenter.ucsf.edu**
- **www.heartlandntbc.org**
- **<http://webnjms.rutgers.edu/ntbcweb/index.html>**